<DOC>
	<DOC>NCT01463254</DOC>
	<brief_summary>This will be a non-comparative prospective observational study of women using Femplant as a primary method of contraception in Pakistan.</brief_summary>
	<brief_title>A Prospective Observational Study of the Clinical Performance of Femplant in Pakistan</brief_title>
	<detailed_description>This will be a non-comparative prospective observational study of women using Femplant as a primary method of contraception in Pakistan. It will be conducted in close collaboration with the Pakistan MoH and Marie Stopes Society, Pakistan in several MoH-affiliated and Marie Stopes Society clinics that have experience with implants and sufficient expected flow of implant users per month. We will enroll a total of 600 women divided into two cohorts in this one-year prospective study: - a prospective cohort consisting of 300 women who will be followed-up 3 and 12 months after enrolment; and - a surveillance cohort of 300 women who will report back to the clinic during 12 months after enrolment only if they have complications, medical problems, pregnancy, or want to remove the implant The main study outcomes are pregnancy, immediate and delayed complications associated with insertion or removal, adverse events, early discontinuation and reasons for discontinuation, and level of women's satisfaction with Femplant services.</detailed_description>
	<criteria>To be eligible for inclusion, a woman must: be aged 1844 years, inclusive be willing to sign an informed consent document agree to return for followup visits have decided to receive Femplant as a method of contraception and met the clinic criteria for eligibility of this method of contraception</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Femplant</keyword>
	<keyword>AE adverse event</keyword>
	<keyword>AIDS acquired immunodeficiency syndrome</keyword>
	<keyword>ALT (SGPT) alanine aminotransferase</keyword>
	<keyword>ART antiretroviral therapy</keyword>
	<keyword>AST (SGOT) aspartate aminotransferase</keyword>
	<keyword>DCF data collection forms</keyword>
	<keyword>DMC Data Monitoring Committee</keyword>
	<keyword>FDA (U.S.) Food and Drug Administration</keyword>
	<keyword>GCP Good Clinical Practice guidelines</keyword>
	<keyword>HB sAg Hepatitis B surface antigen</keyword>
	<keyword>ICH International Conference of Harmonisation</keyword>
	<keyword>IND Investigational New Drug Application</keyword>
	<keyword>IRB Institutional Review Board</keyword>
	<keyword>IU international units</keyword>
	<keyword>mg milligram(s)</keyword>
	<keyword>mm3 cubic millimeter(s)</keyword>
	<keyword>PCR polymerase chain reaction</keyword>
	<keyword>SAE serious adverse event</keyword>
	<keyword>Âµg microgram</keyword>
	<keyword>ULN upper limit of the normal range</keyword>
	<keyword>WB Western Blot</keyword>
</DOC>